Familial risks of breast cancer (BC) are well established but whether BC clusters with other, i.e. discordant, cancers is less certain but of interest for the identification of common genetic and possible environmental factors contributing to a general cancer susceptibility. We apply a novel approach to search for familial associations of BC with other (discordant) cancers based on the Swedish Family-Cancer Database. Relative risks (RRs) were calculated for BC in families with increasing numbers of patients with discordant cancer X, and conversely, familial RRs for cancer X in families with increasing numbers of BC patients. Joint p-values were calculated from independent analyses. The total number of familial BCs was 12,266, 14.9% with one first-degree relative with BC and 1.2% with at least 2 affected relatives. Ovarian and prostate cancers showed the strongest associations with BC (p-value <10
Introduction
About 14% of female breast cancer (BC) patients have a mother or a sister diagnosed with BC and the familial relative risk (RR) is 1.80. 1, 2 It has been estimated that up to 20% of familial breast cancers may harbor a germline variant increasing the risk of BC. 3 Mutations in the most common high-risk genes BRCA1 and BRCA2 confer a 40% to 85% lifetime risk of female BC and also a high risk (10-60%) of ovarian cancer. 4 In the European and African American populations the frequency of deleterious BRCA1/2 mutations is estimated at 1.4% of all breast cancers. 5 The much higher proportions often cited are probably due to founder populations or applied patient selections. In addition, a dozen of other high-or moderate-risk genes have been identified predisposing to BC. 3 Numerous (around 100) low-risk susceptibility loci have been identified but their conferred RRs are low and their combined contribution to the familial risk is calculated to be <20%; because of the low RRs these variants occur frequently without familial background. 6 All high-and moderate-risk genes predisposing to BC increase risks also for other, i.e. discordant, cancers. For example, BRCA1/2 mutations predispose to ovarian, prostate, pancreatic and a few other cancers, and TP53 mutations (Li-Fraumeni syndrome) predispose to brain tumors, sarcomas and a few other tumors. 7 At a population level, discordant associations of BC have been observed with ovarian and prostate cancers, and with lower statistical significance with a few other cancers. 8 Data on associated discordant cancers may be relevant for genetic counseling, and they may provide clues about shared genetic pathways and/or environmental risk factors. We use here stringent statistical criteria in search of discordant familial associations of BC with other cancers using the most recent update of the Swedish Family-Cancer Database. This involves a two-way assessment of familial RRs for BC in families with increasing numbers of patients with cancer X, or conversely in a reverse order, familial RRs for cancer X in families with increasing numbers of patients with BC. In Icelandic and Utah populations confirmation of familial risks have been achieved by assessing the consistency of results over multiple generations.
9,10

Methods
Our Swedish Family-Cancer Database was created by combining the Multi-generation Register, national Cancer Registry (started in 1958), national censuses and Cause of Death Register. This database includes all Swedish people born after 1932 (offspring generation) and their biological parents (parental generation). The latest version of the Swedish Family-Cancer Database contains 15.7 million individuals among which 1.8 million were cancer patients recorded to the end of 2012.
The 3-digital codes of the 7th revision of the International Classification of Diseases (ICD-7) were used to identify 35 most common primary cancers and cancer of unknown primary (CUP). However, as some cancers were rare we displayed data on discordant cancers that showed at least nominal significance at a 5% level in any analyses. The follow-up for cancer in offspring generation (8.5 million individuals) was started from the beginning of 1958, the birth year, or the immigration year, whichever came latest. The follow-up was terminated when a person was diagnosed with cancer, emigrated or died, or at the end of 2012, whichever came first. The number of first-degree relatives (parents and/ or siblings) who was affected with cancer was considered as the family history.
Relative risks (RRs), calculated for the offspring generation, were used as a measure of assessing familial risks by comparing incidence rates for persons with affected relatives to incidence rates for those whose relatives had no cancer. In the two-way comparison, first, RR for female BC was calculated when family history was discordant cancer X, and then in the reverse order RR for cancer X was calculated when family history was female BC. In some analyses cancer X was limited by sex. The two-way analysis is illustrated in Figure  1 . On the left side, RR was calculated for BC; person-years at risk were calculated for all offspring; probands were all firstdegree relatives. On the right side, the reverse analysis was illustrated: RR was calculated for cancer X. For parents and offspring (large majority of familial cases) these comparisons are independent but for siblings the pairs of cases are the same. Significant results in two-way analyses provide support for a true association but a lacking two-way association is no strong evidence against an association because age distributions and case numbers may differ between two-way analyses.
Poisson regression model was used to estimate RRs and corresponding confidence intervals (CI) at 5%, 1% and 0.1% significance levels. These can be combined to calculate a joint significance for independent associations; 8, 10 Figure 1 . Flowchart of calculating the RRs for breast cancer (BC) and cancer X in a two-way analysis. On the left side, RR was calculated for female BC when family history was cancer X; person-years at risk were calculated for all offspring; probands were all first-degree relatives. On the right side, RR was calculated for cancer X when family history was female BC. In some analyses cancer X was limited by sex.
the significant levels of two independent associations are 0.05 and 0.01, the joint significance is 0.0005. 8 Trend tests were performed by modeling the number of familial cancers as a continuous covariate. Potential confounders, including age group, sex, calendar period, residential area and socioeconomic status, were added to the model as covariates. SAS version 9.4 was used to perform the statistical analysis.
The study was approved by the Ethical Committee of Lund University.
Results
The total number of female BCs was 235,316 and of these 76,060 were diagnosed in the 0-80 years offspring generation for which the RRs were calculated. Among offspring with BC, 63,794 (83.9%) had no first-degree relatives diagnosed with BC, while 11,351 (14.9%) had one and 915 (1.2%) had at least two first-degree relatives with concordant BC.
The RR for concordant BC was 1.76 when one firstdegree relative was diagnosed with BC and it increased to 2.74 when two first-degree relatives were diagnosed but it increased no further (1.67) when at least three first-degree relatives were diagnosed (Table 1) ; in families with multiple BC patients the proportion of in situ BCs was largest, which may be the results of intensified screening activity. The first two RRs were significant at a 0.1% and the last RR at a 1% significance level (joint significance 0.001 3 0.001 3 0.01 <10
28
). The reference was families with no BCs in firstdegree relatives and their RR was 1.00 (not shown). A total 
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of 20 discordant cancers were included in Table 1 and all but 3 showed at least one significant association. RRs for BC in prostate cancer families showed a "dose-response" relationship (trend test p < 0.0001): RR was 1.08 in families with one prostate cancer patient, 1.15 in families with two patients and 1.36 in families of three or more patients. For ovarian cancer in probands the trend test was also highly significant (p < 0.0001 and RR was 2.43 when two women were diagnosed with ovarian cancer), and it was also significant for lung cancer (p 5 0.0002) although the RRs were modest. For the remaining 14 discordant associations only a single RR was significant. Curiously, RRs for BC were not increased in families of one melanoma, nonHodgkin lymphoma or leukemia patient but they were high (1.55, 1.48 and 1.49, respectively) in each of these families with two patients. The increase in risk in eye cancer families was due to uveal melanoma (N 5 158, RR 1.17, 95%CI 1.00-1.36); in endocrine gland tumor families the only significant risk was in probands with parathyroid tumors (708, 1.07, 1.00-1.16); for leukemia, the only significant association was with chronic myeloid leukemia (181, 1.18, 1.02-1.37). RRs for all cancer (i.e., RR for BC when first-degree relatives had any cancers) were highly significant and reached 1.62 when at least three first-degree relatives were diagnosed with any cancer, including BC. However, the excess risk decreased to about 1/3 when only discordant cancers were included in first-degree relatives. Table 2 shows results in the reverse analysis, RR for discordant cancers in family members of BC patients. For the same 20 discordant pairs of cancer that were shown in Table 1 , Table  S1 ). The only remarkable findings were high risks for kidney (3.90) and bladder (3.60) cancers and for myeloma (4.87) in families of three or more BC patients, however each association was based on only 2 or 3 families. Similar data on the association of BC with cancers in male relatives is shown in Supplementary Table S2 . Notable findings include RRs of BC of 22.35 in 2 families of three or more cases of stomach cancer and of 1.90 in 15 families of two cases of squamous cell skin cancer. The data on colorectal cancer from these Supplementary tables were collected to Table 3 . BC risk was not increased in families of female colorectal cancer while there was a uniform "dose-response" in families of male colorectal cancers, reaching an RR of 2.64 in families of three or more patients (joint significance < 2.5 3 10
26
).
Discussion
Exploratory studies of the present kind which test multiple hypotheses have implicit concerns about false positive results. Previous studies have reported discordant cancers associated with BC, including ovarian, endometrial, prostate, colon and thyroid cancers, melanoma and non-Hodgkin lymphoma but only the association with ovarian and prostate cancers was reported in multiple earlier studies. [9] [10] [11] In our previous study from an earlier version of the Swedish Family Cancer Database we tested associations of BC with other cancers independently between siblings and parentoffspring pairs to avoid chance findings; we confirmed the associations with ovarian and prostate cancers in both analyses. 8 Weak individual associations were additionally noted for small intestinal, colorectal and lung cancers and for non-Hodgkin lymphoma. However, no previous study had the size or statistical rigor of our study. Confirmed discordant associations in both of the two-way analyses and observing a "dose-response" in increasing RRs by the number of affected probands would add confidence to the findings. The "dose-response" consideration is also informative of the underlying genetic risk (penetrance) and many firstdegree relatives diagnosed with the same cancers signal high penetrance. Significant associations between BC and other sites are probably mainly due to genetic and hormonal effects because, beyond female sex hormone/reproductive factor-related cancers, few shared environmental factors are known for BC and cancer X. For female familial BC the environmental contribution was estimated at only 29%, and among sisters diagnosed with BC their age difference did not influence BC risks which was interpreted as suggesting negligible influence by environmental sharing. 12, 13 BRCA1 carriers are known to be at risk of ovarian cancers and BRCA 2 carriers have an increased risk of ovarian, prostate and pancreatic cancers. 7 However, many other cancers have been reported in BRCA1/2 carriers but whether they represent true excess risks have remained controversial. Colorectal, esophageal and stomach cancers have been suggested to be associated with BRCA1 mutations. [14] [15] [16] Uveal melanoma and also cutaneous melanoma have been ascribed to BRCA2 mutations in some cohorts. Data from a BC clinic indicated that ovarian cancer risk was entirely explained by BRCA1/2 mutations in BC families. 17 Frequencies of BRCA1/2 mutations are not well known in Sweden but one study estimated that <1% of unselected BCs were due to BRCA1 mutations and another study on early onset cases found a BRCA2 mutation frequency of 1/3 of the BRCA1 mutation frequency. 18, 19 Thus, as we found that 16.1% of BCs were familial and if 1% is related to BRCA1/2 it is clear that other factors dominate the present associations. The contribution of other high-risk genes to BC is most likely small because mutations in these are much less frequent than in BRCA1/2.
20 CHEK2*1100-delC is a medium penetrant BC mutation which is also predisposing to a number of other cancers. 21 In a Copenhagen population study on over 80,000 individuals, 0.8% were heterozygous for CHEK2*1100delC and the RR for BC was 2.08. RRs for other associated cancers were 5.76 for stomach cancer, 3.61 for kidney cancer, 3.45 for sarcoma and 1.60 for prostate cancer. 22 In our study ovarian cancer showed one of the strongest two-way association with BC (joint p-values from Tables 1  and 2 were <10 211 ). This is probably mainly due to BRCA1/ 2 mutations and/or hormonal effects. The joint p-values for prostate cancer association were p < 10 211 , probably at least in part contributed by hormonal factors. 23, 24 For melanoma the joint p-values was <10
26
, for both stomach and male colorectal cancer it was <2.5 3 10 26 and for lung cancer it was <5 3 10
25
. The significance level <5 3 10 24 was reached by BC association with pancreatic and eye cancers, leukemia and cancer of unknown primary. A single association of thyroid cancer with BC was significant at p < 0.001. The remaining associations were significant in the two-way comparisons (p < 0.0025): endometrial, testicular, nervous system and endocrine tumors and non-Hodgkin lymphoma. The associations of eye cancer were with uveal melanoma which may suggest the BRCA2 connection. 14, 15 The consistently significant leukemia association was with chronic myeloid leukemia. The associations with endocrine tumors were not uniform and solitary associations with parathyroid and pituitary tumors were noted. For non-Hodgkin lymphoma no individual subtype could be incriminated because the coding system has changed over the years.
Cancer of unknown primary is a fatal metastatic tumor for which primary sites have not been found. 25 Familial associations of this cancer with many primary cancers have been described. 26 It has been suggested that familial associations of cancer of unknown primary, as here with BC, may suggest that in persons diagnosed with cancer of unknown primary, the primary was located in the breast. [27] [28] [29] Single significant associations provide not much confidence in the present kind of studies. However, associations of female kidney and bladder cancers and of myeloma with families of three or more BCs may suggest involvement of rare yet unknown high penetrant genes, or they may simply be due to chance. The results for "All cancers" were remarkable because of the high RRs. In Table1, the RR was 1.62 for families of three or more diverse cancer patients, including BC. The RR was equally high as that for concordant BC (1.67). The population burden of familial cancer in such families (total 3,393 patients) is far higher than in families with concordant BC (26 patients) . This is yet another evidence for shared familial risks between multiple cancers. [30] [31] [32] [33] Even if the present kind of results have major implications for germline genetics of cancer, skeptics may question about the relevance to the clinical practice. First, the above data on the huge population burden of BC in families of many diverse cancers should be an incentive to genetic counseling to suspect genetic risk factors. Second, based on Table 1 , BC risk was high in families where two individuals were diagnosed with melanoma, non-Hodgkin lymphoma or leukemia. Third, as very few cancer predisposing genes have been identified in multiple independent families even in the era of whole-genome sequencing it may be the time to change paradigm of gene finding from a single cancer phenotype to multiple cancer phenotypes. Of course this is not relevant to clinical routine but alert counselors may start observing patterns of cancers that cluster in families.
In summary, applying stringent statistical criteria we confirmed the existence of known and highlighted potentially novel discordant cancer associations with BC. The most significant associations with ovarian and prostate cancers are known and for both hormonal factors are the shared biology with BC. The other cancers with highly significant associations, including melanoma, stomach cancer, male colorectal cancer, chronic myeloid leukemia, cancer of unknown primary, and thyroid, testicular and nervous system cancers and non-Hodgkin lymphoma are novel at least with the current statistical support. These and some solitary BC associations showing a high risk, such as those with female kidney and bladder cancers and with myeloma, should alert genetic counselors seeing BC patients and their family members. Our findings give interesting perspectives for further studies but they suggest that BC shares susceptibility with a number of other cancers for which gene-environment interactions with hormonal and immunological pathways could be involved. A refurbished genetic approach, which was successful in BC and ovarian cancer families and led to discovery of BRCA1/2, might be to target genetic search to BC families presenting with other BC-related cancers.
